Company intelligence / Profile preview

Chronos Therapeutics

Oxford, England, United Kingdomlondonstockexchange.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Chronos Therapeutics is developing small molecule therapeutics for degenerative and behavioral diseases of the brain and nervous system. Its lead compound RDC5 targets ALS. The company has acquired several CNS programs from Shire targeting fatigue in MS and other neurodegenerative/behavioral conditions. Most pipeline assets are in preclinical or discovery stages.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

RDC5

Pre-clinical

Indications: Amyotrophic Lateral Sclerosis

Partnerships

Shire plc—strategic equity investor following asset acquisition deal for CNS development programs.

Beyond the preview

Go deeper on Chronos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chronos Therapeutics.

Explore the full profile